These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24641419)

  • 1. Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
    Bozkurt O; Karaca H; Ciltas A; Kaplan MA; Benekli M; Sevinc A; Demirci U; Eren T; Kodaz H; Isikdogan A; Ozkan M; Buyukberber S
    Asian Pac J Cancer Prev; 2014; 15(4):1845-9. PubMed ID: 24641419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
    Alkis N; Demirci U; Benekli M; Yilmaz U; Isikdogan A; Sevinc A; Ozdemir NY; Koca D; Yetisyigit T; Kaplan MA; Uncu D; Unek T; Gumus M
    J BUON; 2011; 16(1):80-3. PubMed ID: 21674854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
    Francois E; Smith D; Dahan L; Michel C; Perrier H; Mari V; Seitz JF; Follana P; Evesque L; Chamorey E
    J Chemother; 2012 Aug; 24(4):207-11. PubMed ID: 23040684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer.
    Michalaki V; Gennatas S; Gennatas C
    J BUON; 2010; 15(2):270-3. PubMed ID: 20658720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.
    Vormittag L; Kornek GV; Gruhsmann B; Lenauer A; Föger A; Depisch D; Lang F; Scheithauer W
    Anticancer Drugs; 2007 Jul; 18(6):709-12. PubMed ID: 17762401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
    Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
    Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
    Chen Y; Wu J; Cheng K; Li ZP; Luo DY; Qiu M; Gou HF; Yi C; Li Q; Wang X; Yang Y; Cao D; Shen YL; Bi F; Liu JY
    Oncologist; 2019 May; 24(5):591-e165. PubMed ID: 30651398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
    Tsavaris N; Kosmas C; Vadiaka M; Koufos C
    BMC Cancer; 2002; 2():2. PubMed ID: 11860608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.
    Gyldenkerne N; Glimelius B; Frödin JE; Kjaer M; Pfeiffer P; Hansen F; Keldsen N; Sandberg E; Jakobsen A
    Acta Oncol; 2004; 43(3):276-9. PubMed ID: 15244251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer.
    Batra A; Rigo R; Hannouf MB; Cheung WY
    Clin Colorectal Cancer; 2021 Jun; 20(2):e75-e81. PubMed ID: 33268287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
    Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer.
    Cheng K; Chen Y; Li LH; Liu JY
    J Cancer Res Ther; 2013; 9(4):727-9. PubMed ID: 24518728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
    Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
    Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study.
    Michels J; Geldart T; Darby A; Craddock L; Iveson A; Richardson L; Iveson T
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):431-5. PubMed ID: 16909964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
    Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.
    Ghiringhelli F; Vincent J; Bengrine L; Borg C; Jouve JL; Loffroy R; Guiu B; Blanc J; Bertaut A
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2357-2363. PubMed ID: 31273511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
    J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
    Nishina T; Moriwaki T; Shimada M; Higashijima J; Sakai Y; Masuishi T; Ozeki M; Amagai K; Negoro Y; Indo S; Denda T; Sato M; Yamamoto Y; Nakajima G; Mizuta M; Takahashi I; Hiroshima Y; Ishida H; Maeba T; Hyodo I
    Clin Colorectal Cancer; 2016 Sep; 15(3):236-42. PubMed ID: 26778644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Gunasekara NS; Faulds D
    Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.